Contact Information: At RegeneRx: At the Financial |
RegeneRx President/CEO J.J. Finkelstein To be Featured Guest on BIOTECH TODAY Radio Program RegeneRx President/CEO J.J. Finkelstein To be Featured Guest on BIOTECH TODAY Radio Program [Listen to Broadcast] October 1, 2003 — Bethesda, Md RegeneRx Biopharmaceuticals, Inc., (OTCBB: RGRX, www.regenerx.com) today announced that President and CEO J.J. Finkelstein is scheduled to appear as a featured guest on Biotech Today, a New Media Internet radio show carried by World Talk Radio. The interview will air live at 5 p.m. Eastern on Thursday, October 2. The live and archived broadcast can be accessed at the following Internet link: On the program, Finkelstein will discuss the Company’s mission, market opportunity, and therapeutic platform, which targets the multibillion dollar wound-healing market. Under an exclusive worldwide license from the National Institute of Health, the Company is developing a therapy called Thymosin Beta 4 (Tß4) for the treatment of acute and chronic wounds and for the treatment of a variety of human diseases involving tissue and organ repair. Tß4 is a naturally occurring 43-amino acid peptide that is vital for the repair and remodeling of injured tissues. Tß4 exhibits potent anti-inflammatory properties, is non-toxic, active systemically and topically, and can be produced synthetically at low cost. Unlike other prospective wound treatments, it is not a growth factor. RegeneRx holds several patents related to the technology, and has numerous patent applications pending. The Company has initiated human clinical trials with Tß4 for the treatment of chronic dermal wounds. The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the regulatory approval process and the ongoing and prospective development and commercialization of T?4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of clinical trials, product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company. |
